![Impact of preexisting proteinuria on the development of regorafenib-induced problematic proteinuria in real-world metastatic colorectal cancer treatment | Scientific Reports Impact of preexisting proteinuria on the development of regorafenib-induced problematic proteinuria in real-world metastatic colorectal cancer treatment | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-024-55727-w/MediaObjects/41598_2024_55727_Fig1_HTML.png)
Impact of preexisting proteinuria on the development of regorafenib-induced problematic proteinuria in real-world metastatic colorectal cancer treatment | Scientific Reports
![Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC) | British Journal of Cancer Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC) | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-022-01892-6/MediaObjects/41416_2022_1892_Fig1_HTML.png)
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC) | British Journal of Cancer
![Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial | Trials | Full Text Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial | Trials | Full Text](https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13063-019-3917-z/MediaObjects/13063_2019_3917_Fig1_HTML.png)
Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial | Trials | Full Text
![Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis | European Journal of Clinical Pharmacology Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis | European Journal of Clinical Pharmacology](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00228-013-1598-1/MediaObjects/228_2013_1598_Fig5_HTML.gif)
Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis | European Journal of Clinical Pharmacology
pan-Canadian Oncology Drug Review Final Clinical Guidance Report Regorafenib (Stivarga) for Hepatocellular Carcinoma
![The interaction of sorafenib and regorafenib with membranes is modulated by their lipid composition - ScienceDirect The interaction of sorafenib and regorafenib with membranes is modulated by their lipid composition - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0005273616302851-fx1.jpg)
The interaction of sorafenib and regorafenib with membranes is modulated by their lipid composition - ScienceDirect
![Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment | Supportive Care in Cancer Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment | Supportive Care in Cancer](https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00520-022-07381-z/MediaObjects/520_2022_7381_Fig2_HTML.png)
Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment | Supportive Care in Cancer
![Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice - Fabien Calcagno, Sabrina Lenoble, Zaher Lakkis, Thierry Nguyen, Samuel Limat, Christophe Borg, Marine Jary, Stefano Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice - Fabien Calcagno, Sabrina Lenoble, Zaher Lakkis, Thierry Nguyen, Samuel Limat, Christophe Borg, Marine Jary, Stefano](https://journals.sagepub.com/cms/10.4137/CMO.S38335/asset/images/large/10.4137_cmo.s38335-fig2.jpeg)
Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice - Fabien Calcagno, Sabrina Lenoble, Zaher Lakkis, Thierry Nguyen, Samuel Limat, Christophe Borg, Marine Jary, Stefano
![Six-step synthesis of regorafenib 30 synthesized from simple materials | Download Scientific Diagram Six-step synthesis of regorafenib 30 synthesized from simple materials | Download Scientific Diagram](https://www.researchgate.net/publication/358973389/figure/fig4/AS:11431281088015751@1664935019445/Six-step-synthesis-of-regorafenib-30-synthesized-from-simple-materials.png)
Six-step synthesis of regorafenib 30 synthesized from simple materials | Download Scientific Diagram
![The interaction of sorafenib and regorafenib with membranes is modulated by their lipid composition - ScienceDirect The interaction of sorafenib and regorafenib with membranes is modulated by their lipid composition - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0005273616302851-gr6.jpg)